Structure Therapeutics Inc. (NASDAQ: GPCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $80.00 price target on the stock.